Overview
Catherine Stehman-Breen is a Venture Partner at F-Prime [1][4] and a biopharmaceutical executive and physician-scientist with over 20 years of industry experience [2]. Stehman-Breen currently serves as Chief Executive Officer of Winnow Therapeutics [3] and holds board positions at Tenaya Therapeutics and Dyne Therapeutics [5][6]. Previously, Stehman-Breen served as Chief Executive Officer of Chroma Medicine from November 2020 to January 2025 [10] and held board membership at Generation Bio [7]. Stehman-Breen also worked as an Entrepreneur In Residence and later Atlas Advisor at Atlas Venture [8][9]. Stehman-Breen holds an MD in Medicine from the University of Chicago Pritzker School of Medicine [11], a Master's Degree in Epidemiology from the University of Washington [12], and a Bachelor of Arts in Biology and Psychology from Colby College [13].
Profile introduction
Highly experienced biopharmaceutical executive and physician-scientist with 20+ years of industry experience. Significant success in building and leading high performing teams at both large and small companies.
Career history
- Chief Executive OfficerAug 2025 to presentWinnow Therapeutics
- Venture PartnerMar 2025 to presentF-Prime
- Member Board of DirectorsMay 2020 to presentTenaya Therapeutics
- Member Board of DirectorsJun 2019 to presentDyne Therapeutics
- Member Board of DirectorsJan 2018 to Feb 2026Generation Bio
- Atlas AdvisorJun 2019 to Sep 2025Atlas Venture
- Entrepreneur In ResidenceMar 2018 to Jun 2019Atlas Venture
- Chief Executive OfficerNov 2020 to Jan 2025Chroma Medicine
Education
- MD, Medicine1986 - 1990The University of Chicago Pritzker School of Medicine
Master's Degree, Epidemiology1994 - 1996University of Washington
Bachelor of Arts (BA), Biology and Psychology1981 - 1985Colby College
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.